| Detected | Trial | Change |
|---|---|---|
| 2026-06-06 | NCT07570173 A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia… |
date change Primary completion pushed: 2029-02-10 -> 2033-10-18 |
| 2026-06-06 | NCT07570173 A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia… |
date change Completion pushed: 2029-10-02 -> 2033-10-18 |
| 2026-05-29 | NCT04521231 A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-29 | NCT04521231 A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+… |
Enrollment reduced: 281 -> 181 participants |
| 2026-05-21 | NCT04994717 Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-21 | NCT04994717 Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard… |
date change Completion moved earlier: 2031-07-01 -> 2031-05-12 |
| 2026-05-21 | NCT07153796 A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-21 | NCT07153796 A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in… |
Enrollment reduced: 60 -> 3 participants |
| 2026-05-20 | NCT07387926 Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory… |
Primary endpoint(s) modified |
| 2026-05-20 | NCT07387926 Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory… |
date change Primary completion pushed: 2033-01-10 -> 2033-07-18 |
| 2026-05-20 | NCT07387926 Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory… |
date change Completion pushed: 2035-12-12 -> 2036-06-18 |
| 2026-05-16 | NCT07134088 A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-14 | NCT07454226 ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL |
Recruitment opened |
| 2026-05-14 | NCT07454226 ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL |
Enrollment increased: 30 -> 92 participants |
| 2026-05-14 | NCT07493161 Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL |
Recruitment opened |
| 2026-05-14 | NCT07493161 Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL |
Enrollment increased: 100 -> 110 participants |
| 2026-05-14 | NCT07495631 Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult… |
Recruitment opened |
| 2026-05-14 | NCT07495631 Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult… |
Primary endpoint(s) modified |
| 2026-05-14 | NCT07495631 Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult… |
Enrollment reduced: 80 -> 43 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07643103 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative… | Phase 2 | Not Yet Recruiting |
| 2026-06-09 | NCT07636564 Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute… | Phase 2 | Not Yet Recruiting |
| 2026-05-22 | NCT07604233 Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML | Phase 1/2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or… | Acute Lymphoblastic Leukemia | Recruiting |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk… | B Acute Lymphoblastic Leukemia | Recruiting |
| NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | Leukemia, Acute Lymphoblastic | Recruiting |
| NCT07223190 | A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults… | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Not Yet Recruiting |
| NCT07476729 | International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020… | B-Cell Acute Lymphoblastic Leukaemia | Not Yet Recruiting |
| NCT04530565 | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or… | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Active, Not Recruiting |
| NCT04994717 | Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard… | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | Active, Not Recruiting |
| NCT03914625 | A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With… | B Acute Lymphoblastic Leukemia | Active, Not Recruiting |
| NCT02003222 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly… | Acute Lymphoblastic Leukemia | Active, Not Recruiting |
| NCT02101853 | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic… | Recurrent B Acute Lymphoblastic Leukemia | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07570173 | A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia… | B-cell Acute Lymphoblastic Leukemia | Recruiting |
| Phase 2 | |||
| NCT07222579 | Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed… | CD19 Positive | Recruiting |
| NCT05519579 | Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab… | Acute Lymphoblastic Leukemia | Recruiting |
| NCT06533748 | Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia… | Acute Lymphoblastic Leukemia | Recruiting |
| NCT07564453 | Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute… | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Recruiting |
| NCT06570798 | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | Systemic Lupus Erythematosus | Recruiting |
| NCT05645718 | Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and… | Leukemia | Recruiting |
| NCT02877303 | Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in… | B Acute Lymphoblastic Leukemia | Recruiting |
| NCT03263572 | Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With… | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recruiting |
| NCT03739814 | Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients… | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Recruiting |
| NCT06124157 | A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With… | B Acute Lymphoblastic Leukemia | Recruiting |
| NCT06317662 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer… | Acute Leukemia of Ambiguous Lineage | Recruiting |
| NCT06054113 | Study of Blinatumomab Administration in Chinese Pediatric Participants With… | B Precursor Acute Lymphoblastic Leukemia | Active, Not Recruiting |
| NCT03147612 | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With… | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Active, Not Recruiting |
| NCT04329325 | Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia… | Acute Lymphoblastic Leukemia | Active, Not Recruiting |